Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures

J. D. Steeves, D. Lammertse, A. Curt, J. W. Fawcett, M. H. Tuszynski, J. F. Ditunno, P. H. Ellaway, M. G. Fehlings, James D Guest, N. Kleitman, P. F. Bartlett, A. R. Blight, V. Dietz, B. H. Dobkin, R. Grossman, D. Short, M. Nakamura, W. P. Coleman, M. Gaviria, A. Privat

Research output: Contribution to journalArticle

293 Citations (Scopus)

Abstract

An international panel reviewed the methodology for clinical trials of spinal cord injury (SCI), and provided recommendations for the valid conduct of future trials. This is the second of four papers. It examines clinical trial end points that have been used previously, reviews alternative outcome tools and identifies unmet needs for demonstrating the efficacy of an experimental intervention after SCI. The panel focused on outcome measures that are relevant to clinical trials of experimental cell-based and pharmaceutical drug treatments. Outcome measures are of three main classes: (1) those that provide an anatomical or neurological assessment for the connectivity of the spinal cord, (2) those that categorize a subject's functional ability to engage in activities of daily living, and (3) those that measure an individual's quality of life (QoL). The American Spinal Injury Association impairment scale forms the standard basis for measuring neurologic outcomes. Various electrophysiological measures and imaging tools are in development, which may provide more precise information on functional changes following treatment and/or the therapeutic action of experimental agents. When compared to appropriate controls, an improved functional outcome, in response to an experimental treatment, is the necessary goal of a clinical trial program. Several new functional outcome tools are being developed for measuring an individual's ability to engage in activities of daily living. Such clinical end points will need to be incorporated into Phase 2 and Phase 3 trials. QoL measures often do not correlate tightly with the above outcome tools, but may need to form part of Phase 3 trial measures.

Original languageEnglish
Pages (from-to)206-221
Number of pages16
JournalSpinal Cord
Volume45
Issue number3
DOIs
StatePublished - Mar 30 2007

Fingerprint

Spinal Cord Injuries
Outcome Assessment (Health Care)
Clinical Trials
Guidelines
Activities of Daily Living
Quality of Life
Therapeutics
Pharmaceutical Preparations
Nervous System
Spinal Cord

Keywords

  • Clinical trial
  • Functional recovery
  • Neurologic assessment
  • Outcome measures
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Steeves, J. D., Lammertse, D., Curt, A., Fawcett, J. W., Tuszynski, M. H., Ditunno, J. F., ... Privat, A. (2007). Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures. Spinal Cord, 45(3), 206-221. https://doi.org/10.1038/sj.sc.3102008

Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel : Clinical trial outcome measures. / Steeves, J. D.; Lammertse, D.; Curt, A.; Fawcett, J. W.; Tuszynski, M. H.; Ditunno, J. F.; Ellaway, P. H.; Fehlings, M. G.; Guest, James D; Kleitman, N.; Bartlett, P. F.; Blight, A. R.; Dietz, V.; Dobkin, B. H.; Grossman, R.; Short, D.; Nakamura, M.; Coleman, W. P.; Gaviria, M.; Privat, A.

In: Spinal Cord, Vol. 45, No. 3, 30.03.2007, p. 206-221.

Research output: Contribution to journalArticle

Steeves, JD, Lammertse, D, Curt, A, Fawcett, JW, Tuszynski, MH, Ditunno, JF, Ellaway, PH, Fehlings, MG, Guest, JD, Kleitman, N, Bartlett, PF, Blight, AR, Dietz, V, Dobkin, BH, Grossman, R, Short, D, Nakamura, M, Coleman, WP, Gaviria, M & Privat, A 2007, 'Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures', Spinal Cord, vol. 45, no. 3, pp. 206-221. https://doi.org/10.1038/sj.sc.3102008
Steeves, J. D. ; Lammertse, D. ; Curt, A. ; Fawcett, J. W. ; Tuszynski, M. H. ; Ditunno, J. F. ; Ellaway, P. H. ; Fehlings, M. G. ; Guest, James D ; Kleitman, N. ; Bartlett, P. F. ; Blight, A. R. ; Dietz, V. ; Dobkin, B. H. ; Grossman, R. ; Short, D. ; Nakamura, M. ; Coleman, W. P. ; Gaviria, M. ; Privat, A. / Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel : Clinical trial outcome measures. In: Spinal Cord. 2007 ; Vol. 45, No. 3. pp. 206-221.
@article{6644528b1e944068a5a82fa342931db6,
title = "Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures",
abstract = "An international panel reviewed the methodology for clinical trials of spinal cord injury (SCI), and provided recommendations for the valid conduct of future trials. This is the second of four papers. It examines clinical trial end points that have been used previously, reviews alternative outcome tools and identifies unmet needs for demonstrating the efficacy of an experimental intervention after SCI. The panel focused on outcome measures that are relevant to clinical trials of experimental cell-based and pharmaceutical drug treatments. Outcome measures are of three main classes: (1) those that provide an anatomical or neurological assessment for the connectivity of the spinal cord, (2) those that categorize a subject's functional ability to engage in activities of daily living, and (3) those that measure an individual's quality of life (QoL). The American Spinal Injury Association impairment scale forms the standard basis for measuring neurologic outcomes. Various electrophysiological measures and imaging tools are in development, which may provide more precise information on functional changes following treatment and/or the therapeutic action of experimental agents. When compared to appropriate controls, an improved functional outcome, in response to an experimental treatment, is the necessary goal of a clinical trial program. Several new functional outcome tools are being developed for measuring an individual's ability to engage in activities of daily living. Such clinical end points will need to be incorporated into Phase 2 and Phase 3 trials. QoL measures often do not correlate tightly with the above outcome tools, but may need to form part of Phase 3 trial measures.",
keywords = "Clinical trial, Functional recovery, Neurologic assessment, Outcome measures, Spinal cord injury",
author = "Steeves, {J. D.} and D. Lammertse and A. Curt and Fawcett, {J. W.} and Tuszynski, {M. H.} and Ditunno, {J. F.} and Ellaway, {P. H.} and Fehlings, {M. G.} and Guest, {James D} and N. Kleitman and Bartlett, {P. F.} and Blight, {A. R.} and V. Dietz and Dobkin, {B. H.} and R. Grossman and D. Short and M. Nakamura and Coleman, {W. P.} and M. Gaviria and A. Privat",
year = "2007",
month = "3",
day = "30",
doi = "10.1038/sj.sc.3102008",
language = "English",
volume = "45",
pages = "206--221",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel

T2 - Clinical trial outcome measures

AU - Steeves, J. D.

AU - Lammertse, D.

AU - Curt, A.

AU - Fawcett, J. W.

AU - Tuszynski, M. H.

AU - Ditunno, J. F.

AU - Ellaway, P. H.

AU - Fehlings, M. G.

AU - Guest, James D

AU - Kleitman, N.

AU - Bartlett, P. F.

AU - Blight, A. R.

AU - Dietz, V.

AU - Dobkin, B. H.

AU - Grossman, R.

AU - Short, D.

AU - Nakamura, M.

AU - Coleman, W. P.

AU - Gaviria, M.

AU - Privat, A.

PY - 2007/3/30

Y1 - 2007/3/30

N2 - An international panel reviewed the methodology for clinical trials of spinal cord injury (SCI), and provided recommendations for the valid conduct of future trials. This is the second of four papers. It examines clinical trial end points that have been used previously, reviews alternative outcome tools and identifies unmet needs for demonstrating the efficacy of an experimental intervention after SCI. The panel focused on outcome measures that are relevant to clinical trials of experimental cell-based and pharmaceutical drug treatments. Outcome measures are of three main classes: (1) those that provide an anatomical or neurological assessment for the connectivity of the spinal cord, (2) those that categorize a subject's functional ability to engage in activities of daily living, and (3) those that measure an individual's quality of life (QoL). The American Spinal Injury Association impairment scale forms the standard basis for measuring neurologic outcomes. Various electrophysiological measures and imaging tools are in development, which may provide more precise information on functional changes following treatment and/or the therapeutic action of experimental agents. When compared to appropriate controls, an improved functional outcome, in response to an experimental treatment, is the necessary goal of a clinical trial program. Several new functional outcome tools are being developed for measuring an individual's ability to engage in activities of daily living. Such clinical end points will need to be incorporated into Phase 2 and Phase 3 trials. QoL measures often do not correlate tightly with the above outcome tools, but may need to form part of Phase 3 trial measures.

AB - An international panel reviewed the methodology for clinical trials of spinal cord injury (SCI), and provided recommendations for the valid conduct of future trials. This is the second of four papers. It examines clinical trial end points that have been used previously, reviews alternative outcome tools and identifies unmet needs for demonstrating the efficacy of an experimental intervention after SCI. The panel focused on outcome measures that are relevant to clinical trials of experimental cell-based and pharmaceutical drug treatments. Outcome measures are of three main classes: (1) those that provide an anatomical or neurological assessment for the connectivity of the spinal cord, (2) those that categorize a subject's functional ability to engage in activities of daily living, and (3) those that measure an individual's quality of life (QoL). The American Spinal Injury Association impairment scale forms the standard basis for measuring neurologic outcomes. Various electrophysiological measures and imaging tools are in development, which may provide more precise information on functional changes following treatment and/or the therapeutic action of experimental agents. When compared to appropriate controls, an improved functional outcome, in response to an experimental treatment, is the necessary goal of a clinical trial program. Several new functional outcome tools are being developed for measuring an individual's ability to engage in activities of daily living. Such clinical end points will need to be incorporated into Phase 2 and Phase 3 trials. QoL measures often do not correlate tightly with the above outcome tools, but may need to form part of Phase 3 trial measures.

KW - Clinical trial

KW - Functional recovery

KW - Neurologic assessment

KW - Outcome measures

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=33847339738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847339738&partnerID=8YFLogxK

U2 - 10.1038/sj.sc.3102008

DO - 10.1038/sj.sc.3102008

M3 - Article

C2 - 17179972

AN - SCOPUS:33847339738

VL - 45

SP - 206

EP - 221

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 3

ER -